Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1946-1949

  Weber, Britta ^a   Sorensen, Boe S ^a   Knap, Marianne Marquard ^a   Madsen, Hans Henrik ^a   Nexo, Ebba ^a   Meldgaard, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bone metastases; Complete response; EGFR mutation; Erlotinib; NSCLC

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; NAVELBINE;

ADULT; ARTICLE; BONE METASTASIS; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SKIN TOXICITY; SYMPTOM; TREATMENT OUTCOME;

EID: 80054919477     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822e71f2     Document Type: Article

References (10)

1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
2. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008;26: 1472-1478.
3. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
5. Reguart N, Cardona AF, Rosell R. Role of erlotinib in first-line and maintenance treatment of advanced non-small cell lung cancer. Cancer Manag Res 2010;2:143-156.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
7. Yung TK, Chan KC, Mok TS, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009;15:2076-2084.
8. He C, Liu M, Zhou C, et al. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small cell lung cancer. Int J Cancer 2009;125:2393-2399.
9. Riely GJ. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. Lung Cancer 2008;60(Suppl 2):S19-S22. (Pubitemid 351726033)
10. Takamochi K, Suzuki K, Sugimura H, et al. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer 2007;58: 149-155. (Pubitemid 47379958)